Biofabri was founded in 2008 with the strong vision of researching and
developing new vaccines and immunotherapy products for Human Health
For a healthier planet
Vaccines and immunotherapy
Biofabri has extensive experience in researching and developing vaccines against viral, bacterial and parasitic diseases.
MTBVAC is the only live-attenuated M. tuberculosis vaccine evaluated in clinical trials that has demonstrated safety, efficacy and immunogenicity in both preclinical and clinical studies, making it one of the most promising TB vaccines worldwide.